Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Kavita Nair

Concepts (213)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Multiple Sclerosis
7
2023
434
2.030
Why?
Insurance, Pharmaceutical Services
6
2020
23
1.420
Why?
Managed Care Programs
6
2014
137
1.330
Why?
Drugs, Generic
3
2021
28
1.320
Why?
Chronic Disease
6
2020
1824
0.960
Why?
Multiple Sclerosis, Relapsing-Remitting
3
2022
66
0.910
Why?
Drug Compounding
1
2026
106
0.910
Why?
Anti-Obesity Agents
1
2026
67
0.900
Why?
Prescription Drugs
2
2021
110
0.880
Why?
Glucagon-Like Peptides
1
2026
76
0.840
Why?
Drug Costs
2
2025
115
0.800
Why?
Health Resources
2
2016
130
0.750
Why?
Choice Behavior
2
2020
179
0.730
Why?
Cost Sharing
3
2020
23
0.710
Why?
Insurance Benefits
3
2010
12
0.690
Why?
Nervous System Diseases
2
2023
286
0.680
Why?
Retinal Degeneration
1
2021
40
0.650
Why?
Health Services
2
2009
112
0.540
Why?
Health Expenditures
5
2017
196
0.500
Why?
Medicare Part D
2
2021
23
0.490
Why?
Hypertension
2
2014
1270
0.440
Why?
Chlorthalidone
1
2014
3
0.440
Why?
Hydrochlorothiazide
1
2014
7
0.440
Why?
Insurance Coverage
2
2011
246
0.440
Why?
Hospital Costs
1
2016
127
0.430
Why?
Patient Admission
1
2016
216
0.400
Why?
Practice Patterns, Physicians'
2
2021
1370
0.390
Why?
Angiotensin II Type 1 Receptor Blockers
1
2013
39
0.390
Why?
Tetrazoles
1
2013
50
0.390
Why?
Insurance, Health
3
2016
315
0.390
Why?
Immunologic Factors
2
2015
244
0.380
Why?
Antihypertensive Agents
2
2014
519
0.370
Why?
Arthritis, Gouty
1
2012
13
0.360
Why?
Fibric Acids
1
2012
2
0.360
Why?
Gout Suppressants
1
2012
18
0.360
Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2012
344
0.360
Why?
Acute Coronary Syndrome
1
2016
299
0.360
Why?
Drug Labeling
1
2012
36
0.360
Why?
Imidazoles
1
2013
244
0.360
Why?
Absenteeism
1
2012
51
0.360
Why?
Medicare
3
2025
907
0.350
Why?
Off-Label Use
1
2012
50
0.350
Why?
Health Care Costs
2
2012
418
0.340
Why?
Antibodies, Monoclonal, Humanized
4
2025
992
0.340
Why?
Inpatients
1
2016
538
0.340
Why?
Hospital Mortality
1
2016
1037
0.330
Why?
United States
15
2025
16041
0.320
Why?
Diagnostic Tests, Routine
1
2011
108
0.310
Why?
Blood Pressure
2
2014
1761
0.310
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
2
2012
448
0.300
Why?
Retrospective Studies
15
2024
17291
0.300
Why?
Health Benefit Plans, Employee
1
2009
24
0.290
Why?
Adrenal Cortex Hormones
1
2012
483
0.290
Why?
Humans
37
2026
145625
0.280
Why?
Dyslipidemias
2
2012
184
0.280
Why?
Antibodies, Monoclonal
3
2012
1511
0.270
Why?
Program Development
1
2010
365
0.270
Why?
Middle Aged
19
2024
36359
0.270
Why?
Autoimmune Diseases
1
2012
466
0.270
Why?
Loratadine
2
2005
2
0.260
Why?
Negotiating
2
2025
34
0.250
Why?
Male
24
2025
73014
0.250
Why?
Diabetes Mellitus
3
2017
1101
0.250
Why?
Nonprescription Drugs
2
2005
68
0.250
Why?
Oklahoma
1
2026
21
0.240
Why?
Female
24
2025
79080
0.240
Why?
Antirheumatic Agents
1
2009
309
0.230
Why?
Adult
17
2024
40821
0.230
Why?
Models, Economic
2
2016
63
0.220
Why?
Stiff-Person Syndrome
1
2024
14
0.220
Why?
Drug Prescriptions
3
2005
290
0.210
Why?
Infusions, Intravenous
2
2023
429
0.210
Why?
Lupus Vasculitis, Central Nervous System
1
2024
14
0.210
Why?
Aquaporin 4
1
2024
101
0.200
Why?
Aged
15
2025
26251
0.200
Why?
Neurofilament Proteins
1
2024
83
0.200
Why?
Glial Fibrillary Acidic Protein
1
2024
124
0.200
Why?
Insurance Claim Review
3
2017
85
0.200
Why?
Dose-Response Relationship, Drug
3
2014
2018
0.200
Why?
Neurology
2
2023
107
0.200
Why?
Natalizumab
2
2015
30
0.190
Why?
Prescription Fees
1
2003
4
0.190
Why?
Neuromyelitis Optica
1
2024
135
0.190
Why?
Quality Indicators, Health Care
1
2005
340
0.190
Why?
Antineoplastic Agents, Immunological
1
2025
200
0.190
Why?
Patient Outcome Assessment
1
2023
128
0.180
Why?
Metabolic Networks and Pathways
1
2022
175
0.170
Why?
Information Services
1
2001
42
0.170
Why?
Cost-Benefit Analysis
5
2025
632
0.170
Why?
Young Adult
8
2024
14240
0.170
Why?
Myeloid Cells
1
2022
149
0.170
Why?
Neurologists
1
2021
22
0.160
Why?
Atrophy
1
2021
199
0.160
Why?
Infliximab
2
2012
107
0.160
Why?
Community Participation
1
2001
128
0.160
Why?
Rituximab
1
2021
208
0.150
Why?
Attitude to Health
1
2003
419
0.150
Why?
Arthritis, Rheumatoid
1
2009
1184
0.150
Why?
Dementia
1
2023
322
0.140
Why?
Patient Satisfaction
1
2003
698
0.140
Why?
Cross-Sectional Studies
3
2026
5875
0.140
Why?
Cohort Studies
4
2013
6045
0.130
Why?
B-Lymphocytes
1
2022
884
0.130
Why?
Adolescent
7
2024
22451
0.120
Why?
Pharmaceutical Services
2
2011
76
0.120
Why?
Drug Monitoring
2
2010
399
0.120
Why?
Protein Kinase Inhibitors
1
2022
982
0.120
Why?
Carcinoma, Non-Small-Cell Lung
1
2025
1194
0.120
Why?
Models, Statistical
1
2020
667
0.110
Why?
Drug Utilization Review
3
2005
60
0.110
Why?
Aged, 80 and over
5
2025
8351
0.110
Why?
Systole
1
2014
179
0.100
Why?
Losartan
1
2013
13
0.100
Why?
Valsartan
1
2013
33
0.100
Why?
Linear Models
1
2016
847
0.100
Why?
Formularies as Topic
2
2003
3
0.100
Why?
Ambulatory Care
2
2023
627
0.100
Why?
Biphenyl Compounds
1
2013
67
0.100
Why?
Valine
1
2013
84
0.100
Why?
Drug Substitution
1
2013
62
0.100
Why?
Biomarkers
1
2024
4329
0.090
Why?
Population Surveillance
1
2016
477
0.090
Why?
Contraindications
1
2012
88
0.090
Why?
Gemfibrozil
1
2012
9
0.090
Why?
Simvastatin
1
2012
58
0.090
Why?
Lung Neoplasms
1
2025
2674
0.090
Why?
Hypolipidemic Agents
1
2012
89
0.090
Why?
Costs and Cost Analysis
1
2012
216
0.090
Why?
Glatiramer Acetate
1
2011
11
0.090
Why?
Mitoxantrone
1
2011
14
0.080
Why?
Age Distribution
1
2012
395
0.080
Why?
Hematologic Tests
1
2011
22
0.080
Why?
United States Food and Drug Administration
1
2012
207
0.080
Why?
Prevalence
3
2024
2852
0.080
Why?
Financing, Personal
1
2011
26
0.080
Why?
Colorado
3
2024
4588
0.080
Why?
Interferon-beta
1
2011
90
0.080
Why?
Poisson Distribution
1
2010
77
0.080
Why?
Clinical Laboratory Techniques
1
2011
96
0.080
Why?
Likelihood Functions
1
2010
138
0.080
Why?
Renal Insufficiency, Chronic
1
2017
639
0.080
Why?
Spine
1
2011
184
0.080
Why?
Length of Stay
1
2016
1342
0.080
Why?
Analysis of Variance
1
2012
1293
0.070
Why?
Severity of Illness Index
2
2017
2910
0.070
Why?
Preferred Provider Organizations
1
2009
3
0.070
Why?
Quality-Adjusted Life Years
2
2024
119
0.070
Why?
Respiratory Function Tests
1
2011
543
0.070
Why?
Drug Therapy, Combination
1
2012
1034
0.070
Why?
Patient Discharge
1
2016
991
0.070
Why?
Private Sector
1
2009
50
0.070
Why?
Transportation
1
2009
54
0.070
Why?
Regression Analysis
2
2009
994
0.070
Why?
Treatment Outcome
2
2014
11744
0.070
Why?
Orthopedic Procedures
1
2011
252
0.070
Why?
North America
1
2009
299
0.070
Why?
Pain Management
1
2011
413
0.070
Why?
Incidence
2
2024
2910
0.070
Why?
Electrocardiography
1
2011
666
0.070
Why?
Tumor Necrosis Factor-alpha
1
2012
1223
0.060
Why?
Research Design
1
2014
1139
0.060
Why?
Surveys and Questionnaires
1
2020
6050
0.060
Why?
Proportional Hazards Models
1
2011
1318
0.060
Why?
Multivariate Analysis
1
2010
1531
0.060
Why?
Electronic Health Records
1
2014
1208
0.060
Why?
Program Evaluation
1
2010
945
0.060
Why?
Patient Acceptance of Health Care
1
2012
880
0.060
Why?
Peptides
1
2011
991
0.060
Why?
Logistic Models
1
2010
2112
0.060
Why?
Anti-Allergic Agents
1
2005
41
0.050
Why?
Time Factors
1
2016
7079
0.050
Why?
Efficiency, Organizational
1
2005
142
0.050
Why?
Benchmarking
1
2005
192
0.050
Why?
Comparative Effectiveness Research
1
2025
170
0.050
Why?
Follow-Up Studies
1
2013
5397
0.050
Why?
Histamine H2 Antagonists
1
2004
22
0.050
Why?
Cholesterol, LDL
1
2005
363
0.050
Why?
Neuroglia
1
2024
176
0.050
Why?
Longitudinal Studies
1
2011
3005
0.050
Why?
Hyperlipidemias
1
2003
120
0.050
Why?
Patient Compliance
2
2003
587
0.040
Why?
Evidence-Based Medicine
1
2005
727
0.040
Why?
Pamphlets
1
2001
26
0.040
Why?
Health Care Surveys
1
2023
538
0.040
Why?
Decision Making
2
2015
987
0.040
Why?
Risk Assessment
1
2010
3678
0.040
Why?
Hypoglycemic Agents
1
2010
1411
0.040
Why?
Students, Pharmacy
1
2001
96
0.040
Why?
Hospitalization
1
2009
2468
0.030
Why?
Magnetic Resonance Imaging
1
2011
3917
0.030
Why?
Child
3
2024
22638
0.030
Why?
Models, Econometric
1
2017
35
0.030
Why?
Recurrence
1
2020
1125
0.030
Why?
Diabetes Mellitus, Type 1
1
2014
3930
0.030
Why?
Case-Control Studies
1
2024
3633
0.030
Why?
Neurons
1
2024
1663
0.030
Why?
Registries
1
2023
2382
0.030
Why?
Glomerular Filtration Rate
1
2017
743
0.020
Why?
Medical Audit
1
2013
77
0.020
Why?
Socioeconomic Factors
1
2017
1323
0.020
Why?
Diabetes Complications
1
2014
219
0.020
Why?
Pandemics
1
2020
1700
0.020
Why?
Decision Support Techniques
1
2015
473
0.020
Why?
Sex Factors
1
2017
2101
0.020
Why?
Databases, Factual
1
2016
1481
0.020
Why?
Age Factors
1
2017
3321
0.020
Why?
Comorbidity
1
2014
1652
0.020
Why?
Randomized Controlled Trials as Topic
1
2015
1754
0.020
Why?
Rhinitis, Allergic, Perennial
1
2005
20
0.010
Why?
California
1
2005
473
0.010
Why?
Coronary Disease
1
2003
380
0.010
Why?
Child, Preschool
1
2016
11888
0.010
Why?
Risk Factors
1
2003
10840
0.000
Why?
Nair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)